The pharmacotherapeutic management of gastroesophageal reflux disease (GERD).
Fiche publication
Date publication
septembre 2020
Journal
Expert opinion on pharmacotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARDOU Marc
Tous les auteurs :
Chapelle N, Ben Ghezala I, Barkun A, Bardou M
Lien Pubmed
Résumé
Gastroesophageal reflux disease (GERD) is a very common worldwide condition, affecting about 15-20% of the whole population, and representing a major burden for health-care systems. Because of its frequency, health physicians - family doctors as well as specialists - should be aware of the different pharmacotherapeutic approaches in managing GERD, according to disease severity.
Mots clés
Gastroesophageal reflux disease, erosive esophagitis, potassium-competitive acid blocker, proton-pump inhibitor, refractory gastroesophageal reflux disease
Référence
Expert Opin Pharmacother. 2020 Sep 7;:1-9